{"pmid":32395220,"pmcid":"PMC7202347","title":"SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.","text":["SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.","Mediterr J Hematol Infect Dis","Abruzzese, Elisabetta","Luciano, Luigiana","D'Agostino, Francesco","Trawinska, Malgorzata Monika","Pane, Fabrizio","De Fabritiis, Paolo","32395220"],"journal":"Mediterr J Hematol Infect Dis","authors":["Abruzzese, Elisabetta","Luciano, Luigiana","D'Agostino, Francesco","Trawinska, Malgorzata Monika","Pane, Fabrizio","De Fabritiis, Paolo"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395220","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4084/MJHID.2020.031","keywords":["abl","cml","covid-19","sars-cov-2","tki"],"link_comment_for":"30671212","locations":["Viral Infection"],"topics":["Case Report"],"weight":1,"_version_":1666627827858931714,"score":9.490897,"similar":[{"pmid":32383276,"title":"Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.","text":["Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.","Br J Clin Pharmacol","Eskazan, Ahmet Emre","32383276"],"journal":"Br J Clin Pharmacol","authors":["Eskazan, Ahmet Emre"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383276","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bcp.14353","keywords":["covid-19","chronic myeloid leukemia","qtc prolongation","sars-cov-2","drug-drug interaction","tyrosine kinase inhibitor"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666419683325116416,"score":97.72553},{"pmid":32394688,"title":"[Chronic granulocytic leukemia with COVID-19 pneumonia: a case report].","text":["[Chronic granulocytic leukemia with COVID-19 pneumonia: a case report].","Zhonghua Xue Ye Xue Za Zhi","Sheng, L S","Li, D J","Zhou, J F","Huang, W","32394688"],"journal":"Zhonghua Xue Ye Xue Za Zhi","authors":["Sheng, L S","Li, D J","Zhou, J F","Huang, W"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394688","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3760/cma.j.issn.0253-2727.2020.0008","topics":["Case Report"],"weight":1,"_version_":1666627827802308608,"score":76.70022},{"pmid":32388230,"title":"Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.","text":["Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.","Leuk Res","Paneesha, S","Pratt, G","Parry, H","Moss, P","32388230"],"journal":"Leuk Res","authors":["Paneesha, S","Pratt, G","Parry, H","Moss, P"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388230","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.leukres.2020.106366","topics":["Case Report"],"weight":1,"_version_":1666428892640968705,"score":61.421665},{"pmid":32424293,"title":"COVID-19 in persons with chronic myeloid leukaemia.","text":["COVID-19 in persons with chronic myeloid leukaemia.","We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.","Leukemia","Li, Weiming","Wang, Danyu","Guo, Jingming","Yuan, Guolin","Yang, Zhuangzhi","Gale, Robert Peter","You, Yong","Chen, Zhichao","Chen, Shiming","Wan, Chucheng","Zhu, Xiaojian","Chang, Wei","Sheng, Lingshuang","Cheng, Hui","Zhang, Youshan","Li, Qing","Qin, Jun","Meng, Li","Jiang, Qian","32424293"],"abstract":["We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation."],"journal":"Leukemia","authors":["Li, Weiming","Wang, Danyu","Guo, Jingming","Yuan, Guolin","Yang, Zhuangzhi","Gale, Robert Peter","You, Yong","Chen, Zhichao","Chen, Shiming","Wan, Chucheng","Zhu, Xiaojian","Chang, Wei","Sheng, Lingshuang","Cheng, Hui","Zhang, Youshan","Li, Qing","Qin, Jun","Meng, Li","Jiang, Qian"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424293","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41375-020-0853-6","locations":["Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Imatinib Mesylate"],"topics":["Prevention"],"weight":1,"_version_":1667352728691539968,"score":56.307396},{"pmid":32149486,"title":"[COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report].","text":["[COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report].","Zhonghua Xue Ye Xue Za Zhi","Chen, Z","Xiong, H","Li, J X","Li, H","Tao, F","Yang, Y T","Wu, B","Tang, W","Teng, J X","Fu, Q","Yang, L","32149486"],"journal":"Zhonghua Xue Ye Xue Za Zhi","authors":["Chen, Z","Xiong, H","Li, J X","Li, H","Tao, F","Yang, Y T","Wu, B","Tang, W","Teng, J X","Fu, Q","Yang, L"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32149486","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.3760/cma.j.issn.0253-2727.2020.0004","topics":["Case Report"],"weight":1,"_version_":1666138492726411265,"score":56.062496}]}